Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 2, 2012

EU Consortium Wins €4.2M to Develop Bioartificial Liver

  • A consortium coordinated by Medicyte will receive €4.2 million (about $5.2 million) in funding from the European commission’s Seventh Framework Program to develop a biomimetic liver that could be used as transplantation therapy for treating metabolic diseases such as hemophilia A, or even as an alternative for solid organ transplantation.

    The Re-Liver program has been established as a collaboration between Medicyte, The Electrospinning Company, and the Universities of Manchester (U.K) and Pisa (Italy). The collaborators aim to reconstitute a standardized, reproducible bioartificial liver organoid (BLO) using healthy human liver as an architectural and biomaterial template. In addition, new diagnostic tools and further products in cell-based applications will be developed and validated. “The combination of our complimentary areas of expertise will give a deeper insight into the complex bioartificial liver design, but is also an innovative approach to develop better and quicker diagnostic tools and cell-based products,” comments Joris Braspenning, Ph.D., Medicyte CEO and CSO. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »